Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study.

Leandro Blas Masaki ShiotaHideaki MiyakeMasayuki TakahashiMototsugu OyaNorihiko Tsuchiya Naoya MasumoriHideyasu MatsuyamaWataru ObaraNobuo ShinoharaKiyohide FujimotoMasahiro NozawaKojiro OhbaChikara OhyamaKatsuyoshi HashineShusuke AkamatsuTomomi KambaKoji MitaMomokazu GotohShuichi TataranoMasato FujisawaYoshihiko Tomita Shoichiro Mukai Keiichi ItoTokiyoshi TanegashimaShoji TokunagaMasatoshi Etonull null

Published in: International journal of urology : official journal of the Japanese Urological Association (2023)

The SNiP-RCC study identified clinical parameters correlated with treatment outcomes in Japanese patients with priorly treated advanced clear cell RCC undergoing nivolumab monotherapy.

Keyphrases

renal cell carcinoma
clinical trial
clear cell
open label
study protocol
newly diagnosed